NCT07148180View on ClinicalTrials.gov

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

February 28, 2026

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Acute Myeloid Leukaemia (AML)LeukemiaBlood CancerBlood Cancers
Interventions
DRUG

Tagraxofusp

A CD123-directed cytotoxin, Single-use vial, via intravenous (into the vein) infusion per protocol.

DRUG

Azacitidine (AZA)

A cytidine nucleoside analog, single-use vial, via intravenous infusion or subcutaneous (under the skin) injection per standard of care.

DRUG

Venetoclax

A BCL-2 inhibitor, tablet, via orally per standard of care.

Trial Locations (2)

02115

Brigham and Women's Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
collaborator

Stemline Therapeutics, Inc.

INDUSTRY

collaborator

Break Through Cancer Foundation

UNKNOWN

lead

Jacqueline Garcia, MD

OTHER